Insider Buying: PureTech Health (LON:PRTC) Insider Acquires £939.44 in Stock

PureTech Health plc (LON:PRTCGet Free Report) insider Sharon Barber-Lui bought 93,944 shares of the stock in a transaction that occurred on Wednesday, July 29th. The stock was acquired at an average price of GBX 1 per share, for a total transaction of £939.44.

Sharon Barber-Lui also recently made the following trade(s):

  • On Tuesday, July 7th, Sharon Barber-Lui purchased 29,868 shares of PureTech Health stock. The shares were bought at an average price of GBX 119 per share, with a total value of £35,542.92.

PureTech Health Stock Down 0.4%

Shares of LON:PRTC opened at GBX 119.12 on Monday. The business’s 50 day moving average is GBX 127.34 and its 200 day moving average is GBX 126.62. PureTech Health plc has a 12-month low of GBX 104.71 and a 12-month high of GBX 146.40. The stock has a market cap of £289.96 million, a price-to-earnings ratio of -2.59 and a beta of 0.79. The company has a quick ratio of 2.51, a current ratio of 6.59 and a debt-to-equity ratio of 6.33.

Analysts Set New Price Targets

Separately, Peel Hunt restated a “buy” rating and set a GBX 508 price target on shares of PureTech Health in a research report on Monday, July 13th. One investment analyst has rated the stock with a Buy rating, According to data from MarketBeat, the stock has a consensus rating of “Buy” and a consensus price target of GBX 508.

Get Our Latest Stock Analysis on PureTech Health

About PureTech Health

(Get Free Report)

PureTech Health plc, a clinical-stage biopharma company, focuses on developing medicines for diseases caused by dysfunctions in the nervous, gastrointestinal, and immune systems. The company is developing a microbiome immune system drug-discovery platform and drug candidates for immune-mediated diseases; and products to induce weight loss and enhance glycaemic control through an orally administered capsule. It is also developing technology and products for screening, diagnosis, and treatment of neurological disorders, such as ADHD, autism, and depression through computer software; noninvasive neurostimulation treatment for psychiatric disorders; and combination therapy for schizophrenia.

Read More

Insider Buying and Selling by Quarter for PureTech Health (LON:PRTC)

Receive News & Ratings for PureTech Health Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for PureTech Health and related companies with MarketBeat.com's FREE daily email newsletter.